4-(5-chloro-benzooxazol-2-yl)-benzoic acid | 884849-06-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(5-chloro-benzooxazol-2-yl)-benzoic acid
• 英文别名: 4-(5-Chloro-1,3-benzoxazol-2-yl)benzoic acid
• CAS: 884849-06-3
• 化学式: C₁₄H₈ClNO₃
• mdl: MFCD07601142
• 分子量: 273.675
• InChiKey: RKFQXPZCXWRHGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(5-chloro-benzooxazol-2-yl)-benzoic acid 在 草酰氯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-(5-Chloro-1,3-benzoxazol-2-YL)benzoyl chloride
  参考文献：
  名称：

  2-Arylbenzoxazoles as CETP inhibitors: Substitution and modification of the α-alkoxyamide moiety

  摘要：

  The development of a series of 2-arylbenzoxazole alpha-alkoxyamide and beta-alkoxyamine inhibitors of cholesteryl ester transfer protein (CETP) is described. Highly fluorinated alpha-alkoxyamides proved to be potent inhibitors of CETP in vitro, and the highly fluorinated 2-arylbenzoxazole beta-alkoxyamine 4 showed a desirable combination of in vitro potency (IC(50) = 151 nM) and oral bioavailability in the mouse. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.046
• 作为产物：
  描述：

  5-chloro-2-(4-methoxycarbonylphenyl)benzo[d]oxazol 在 lithium hydroxide 作用下， 生成 4-(5-chloro-benzooxazol-2-yl)-benzoic acid
  参考文献：
  名称：

  2-Arylbenzoxazoles as CETP inhibitors: Substitution and modification of the α-alkoxyamide moiety

  摘要：

  The development of a series of 2-arylbenzoxazole alpha-alkoxyamide and beta-alkoxyamine inhibitors of cholesteryl ester transfer protein (CETP) is described. Highly fluorinated alpha-alkoxyamides proved to be potent inhibitors of CETP in vitro, and the highly fluorinated 2-arylbenzoxazole beta-alkoxyamine 4 showed a desirable combination of in vitro potency (IC(50) = 151 nM) and oral bioavailability in the mouse. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.046

文献信息

• METHODS FOR TREATING SPINAL MUSCULAR ATROPHY
  申请人：Paushkin Sergey V.

  公开号：US20110086833A1

  公开（公告）日：2011-04-14

  The present invention provides nucleic acid constructs, methods for identifying and validating compounds that increase the inclusion of exon 7 of SMN2 into mRNA transcribed from the SMN2 gene, compounds and pharmaceutical compositions that increase levels of SMN protein produced from the SMN2 gene, and methods for use thereof in treating of SMA.

  本发明提供了核酸构建物，用于识别和验证增加SMN2基因转录的mRNA中exon 7包含量的化合物的方法，增加从SMN2基因产生的SMN蛋白水平的化合物和药物组合物，以及在SMA治疗中使用它们的方法。
• Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases
  申请人：Wilde Richard

  公开号：US20080269191A1

  公开（公告）日：2008-10-30

  The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

  本发明涉及使用本发明的化合物或组合物治疗或预防与mRNA中无意义突变相关的疾病的方法、化合物和组合物。更具体地，本发明涉及用于抑制与mRNA中无意义突变相关的早期翻译终止的方法、化合物和组合物。
• METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH
  申请人：Almstead Neil G.

  公开号：US20110046136A1

  公开（公告）日：2011-02-24

  The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.

  本发明涉及由核酸序列编码的功能性蛋白质，其中包括一个无意义突变。本发明还涉及用于生产由包含无意义突变的核酸序列编码的功能性蛋白质的方法，以及利用这些蛋白质预防、管理和/或治疗与基因中的无意义突变相关的疾病。
• METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH
  申请人：PTC THERAPEUTICS, INC

  公开号：US20160199357A1

  公开（公告）日：2016-07-14

  The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.

  本发明涉及由包含无意义突变的核酸序列编码的功能蛋白质。本发明还涉及用于生产由包含无意义突变的核酸序列编码的功能蛋白质的方法，并使用这些蛋白质预防、管理和/或治疗与基因中的无意义突变相关的疾病。
• Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
  申请人：PTC Therapeutics, Inc.

  公开号：EP2387995A1

  公开（公告）日：2011-11-23

  The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.

  本发明涉及由包含无义突变的核酸序列编码的功能性蛋白质。本发明还涉及生产由包含无义突变的核酸序列编码的功能性蛋白质的方法，以及将这种蛋白质用于预防、控制和/或治疗与基因中的无义突变有关的疾病的方法。